Linked Life Data

15591767

Source:http://linkedlifedata.com/resource/pubmed/id/15591767

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-12-13
pubmed:abstractText
Morphine is a strong and widely used opioid analgesic in pain management, but some adverse effects limit its clinical use at high doses. The clinically available non-opioid antitussive, dextromethorphan (DM) can potentiate the analgesic effect of morphine and decrease the dose of morphine in acute postoperative pain. However, the mechanism underlying this synergistic phenomenon is still not clear. To examine if the potentiation by DM occurs through the descending pain-inhibitory pathways, ketanserin (a 5-HT2 receptor antagonist) and yohimbine (an alpha2-adrenergic receptor antagonist) were employed and found to have no significant effect on the potentiation by DM. Using local delivery of drugs in rats in the present study, potentiation of morphine-induced antinociception by DM was observed via both intrathecal and intracerebroventricular routes, suggesting that both spinal and supraspinal sites are involved. This suggests that the potentiation of morphine-induced antinociception by DM is not mediated by the serotoninergic or adrenergic descending pain-inhibitory pathways. The present results are consistent with findings in clinical studies, which showed that DM can effectively decrease the consumption of morphine in patients suffering from pain. Since DM has excellent clinical potential as a synergistic agent with morphine, further investigating and clarifying the possible pharmacological mechanism of DM are of great importance for future studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1021-7770
pubmed:author
pubmed:copyrightInfo
2004 National Science Council, ROC and S. Karger AG, Basel
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
717-25
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15591767-Adrenergic Agents, pubmed-meshheading:15591767-Adrenergic alpha-Antagonists, pubmed-meshheading:15591767-Analgesics, Opioid, pubmed-meshheading:15591767-Animals, pubmed-meshheading:15591767-Back, pubmed-meshheading:15591767-Dextromethorphan, pubmed-meshheading:15591767-Drug Synergism, pubmed-meshheading:15591767-Injections, Spinal, pubmed-meshheading:15591767-Ketanserin, pubmed-meshheading:15591767-Kinetics, pubmed-meshheading:15591767-Male, pubmed-meshheading:15591767-Morphine, pubmed-meshheading:15591767-Pain, pubmed-meshheading:15591767-Pain Measurement, pubmed-meshheading:15591767-Protein Binding, pubmed-meshheading:15591767-Rats, pubmed-meshheading:15591767-Rats, Sprague-Dawley, pubmed-meshheading:15591767-Receptors, Opioid, mu, pubmed-meshheading:15591767-Serotonin, pubmed-meshheading:15591767-Serotonin Antagonists, pubmed-meshheading:15591767-Spinal Cord, pubmed-meshheading:15591767-Time Factors, pubmed-meshheading:15591767-Yohimbine
pubmed:articleTitle
Dextromethorphan potentiates morphine-induced antinociception at both spinal and supraspinal sites but is not related to the descending serotoninergic or adrenergic pathways.
pubmed:affiliation
Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, ROC.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't